US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma

robot
Abstract generation in progress

The US FDA has approved Bristol Myers Squibb’s cancer drug for the treatment of Hodgkin’s lymphoma. This news is relevant for investors following the pharmaceutical industry and specific companies like Bristol Myers Squibb (BMY).

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin